{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Washaya T"],"funding":["FIC NIH HHS","NIH HHS"],"pagination":["1348"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC12567580"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["17(10)"],"pubmed_abstract":["The HIV-1 epidemic continues to challenge global public health, especially in sub-Saharan Africa. The rise in drug-resistant viruses, particularly pan-resistant strains, threatens treatment effectiveness, hindering progress toward UNAIDS viral suppression goals. This is critical in low-to-middle income countries (LMICs) like Zimbabwe, where treatment options and access to drug resistance testing are limited. This cross-sectional study analyzed 102 genotypes from patients with HIV-1 RNA ≥ 1000 copies/mL after at least 6 months on a dolutegravir (DTG)-based ART. HIV-1 genotyping and drug resistance interpretation were performed using the Stanford HIV Drug Resistance Database. Overall, 62% of genotypes harbored at least one drug resistance mutation, with 27% showing integrase strand transfer "],"journal":["Viruses"],"pubmed_title":["Pan-Resistant HIV-1 Drug Resistance Among Highly Treated Patients with Virological Failure on Dolutegravir-Based Antiretroviral Therapy in Zimbabwe."],"pmcid":["PMC12567580"],"funding_grant_id":["D43 TW011326","1D43TW011326-05"],"pubmed_authors":["Chin'ombe N","Bote S","Mayini J","Munyati S","Manasa J","Washaya T","Chimukangara B"],"additional_accession":[]},"is_claimable":false,"name":"Pan-Resistant HIV-1 Drug Resistance Among Highly Treated Patients with Virological Failure on Dolutegravir-Based Antiretroviral Therapy in Zimbabwe.","description":"The HIV-1 epidemic continues to challenge global public health, especially in sub-Saharan Africa. The rise in drug-resistant viruses, particularly pan-resistant strains, threatens treatment effectiveness, hindering progress toward UNAIDS viral suppression goals. This is critical in low-to-middle income countries (LMICs) like Zimbabwe, where treatment options and access to drug resistance testing are limited. This cross-sectional study analyzed 102 genotypes from patients with HIV-1 RNA ≥ 1000 copies/mL after at least 6 months on a dolutegravir (DTG)-based ART. HIV-1 genotyping and drug resistance interpretation were performed using the Stanford HIV Drug Resistance Database. Overall, 62% of genotypes harbored at least one drug resistance mutation, with 27% showing integrase strand transfer ","dates":{"release":"2025-01-01T00:00:00Z","publication":"2025 Oct","modification":"2026-05-15T03:16:26.937Z","creation":"2026-05-15T03:12:05.179Z"},"accession":"S-EPMC12567580","cross_references":{"pubmed":["41157619"],"doi":["10.3390/v17101348"]}}